| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 117.70 | 39.0% |
| Total Income | 117.70 | 39.0% |
| Expenditure | 116.50 | 18.8% |
| PBT | 2.78 | 127.0% |
| Net Profit | 2.81 | 127.2% |
| OPM | 1.02% | 16.81pp |
| NPM | 2.39% | 14.61pp |
| EPS | 0.05 | 126.3% |
CareDx Reports Q1 2026 Revenue Up 39% and Raises 2026 Guidance
03 May 2026 · 3 May, 6:36 pm
Summary
CareDx reported strong financial results for the first quarter of 2026, with revenue increasing by 39% to $118 million. The growth was primarily driven by higher testing services revenue and contributions from patient and digital solutions. GAAP net income improved to $3 million, compared to a net loss of $10 million in the same quarter of the previous year. The company has raised its full year 2026 revenue guidance to $447 million to $465 million and adjusted EBITDA guidance to $43 million to $57 million.
Key Highlights
- 1
CareDx reported revenue of $118 million for Q1 2026, representing a 39% increase year-over-year.
- 2
Testing services revenue increased by 48% year-over-year to $91 million, with testing services volume up 17% to approximately 54,900.
- 3
Patient and digital solutions revenue grew by 33% year-over-year to $16 million.
- 4
GAAP net income for Q1 2026 was $3 million, compared to a net loss of $10 million in Q1 2025.
- 5
Adjusted EBITDA for Q1 2026 was $19 million, compared to $5 million in Q1 2025.
- 6
The company raised its full year 2026 revenue guidance to a range of $447 million to $465 million.
- 7
CareDx also raised its full year 2026 adjusted EBITDA guidance to a range of $43 million to $57 million.
Management Comments
John W. Hanna
Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses. And we took important strategic steps advancing our lead pipeline asset, AlloHeme, and agreeing to divest the Lab Products business to simplify our operating model and create focus, with the goal of expanding our AEBITDA margins.
Informational and educational content only. Not investment advice.